FDA accepts new drug application from Jansen Invokana (canagliflozin, Cagrenet)

diabetes is the leading cause of renal failure, affecting millions of patients around the world, but there are few effective long-term treatmentsrecently, janssen Pharmaceutical s company janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, http://
announcedtheof the company, http:// that the U.SFDAaccepting the company's application for a new(http://for Invokana (canagliflozin, cagrnet) and grantite it priority review statusCaglenet is a sodium glucose co-transport protein-2 (SGLT2) inhibitor developed by Jansen to help control blood sugar levels in patients with type 2 diabetes by inhibiting the function of SGLT2 and reducing the reabsorption of glucose by the kidneysCaglenet has been approved as an complementary therapy to control blood sugar levels in patients with type 2 diabetes and to help reduce the risk of cardiovascular diseasecagr net will be used in adults with type 2 diabetes with chronic kidney disease (CKD) to reduce the risk of end-stage renal disease (ESKD), elevated serum creatinine, and kidney or cardiovascular deathIf approved, Caglinet would become the first diabetesdrug to treat CKD in patients with type 2 diabetes in 20 years
(http://
The randomized double-blind, placebo-controlled-3 clinical trial (http:// ) was the first clinical trial specifically to the effects of (http:// SGLT2 inhibitors on kidney function A total of 4,401 people with type 2 diabetes with stage 2 or 3 OF CKD were treated results showed that at a median follow-up period of 2.62 years, the risk of ESKD in patients in the Cagle net group was reduced by 30% compared to the control group (HR: 0.70; 95% CI: 0.59-0.82, P-0.00001) MACE risk in patients in the Cagli net group was also reduced by 20% (HR: 0.80, 95% CI: 0.67-0.95, p.01)